Theradigm-HBV immunotherapeutic data

The San Diego company presented Phase I data showing that Theradigm-HBV induced HBV-specific cytotoxic T lymphocytes (CTLs) in normal volunteers.

The volunteers received a single dose of drug followed by a booster at the same dosage five weeks later, CYTL said at the Keystone Conference on Tumor Viruses in Taos, N.M. CTL activity was measured by removing the subject's white blood cells and measuring in vitro their ability to kill cells bearing the HBV antigen at intervals up to 28 days after inoculation. ...